Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Andorra Health Watch.
Press releases published on June 27, 2025
Orphalan Partners with MAP International and the Wilson Disease Association to Provide Life-Changing Medicine to Underserved Communities
GlobeNewswire
·
June 27, 2025
FOR IMMEDIATE RELEASE Orphalan Partners with MAP International and the Wilson Disease Association to Provide Life-Changing Medicine to Underserved Communities Paris, France —27, June, 2025— Orphalan SA, a global pharmaceutical company focused on rare …
Tilray Medical veröffentlicht bahnbrechende Forschungsergebnisse zur Pharmakokinetik von THC- und CBD-Formulierungen
GlobeNewswire
·
June 27, 2025
NEW YORK, June 27, 2025 (GLOBE NEWSWIRE) -- Tilray Medical, ein Geschäftsbereich von Tilray Brands, Inc. („Tilray” oder das „Unternehmen”) (Nasdaq: TLRY; TSX: TLRY) und ein weltweit führender Anbieter von medizinischem Cannabis, der die therapeutische …
Tilray Medical publie une recherche pionnière sur la pharmacocinétique des formulations de THC et de CBD
GlobeNewswire
·
June 27, 2025
NEW YORK, 27 juin 2025 (GLOBE NEWSWIRE) -- Tilray Medical, une division de Tilray Brands, Inc. (« Tilray » ou la « Société ») (Nasdaq : TLRY ; TSX : TLRY) et leader mondial du cannabis thérapeutique, qui favorise l’alliance thérapeutique entre les patients …
Biocon Biologics Receives Health Canada Approval for Yesafili™ (aflibercept); First Global Launch Scheduled for July 2025
GlobeNewswire
·
June 27, 2025
TORONTO, Ontario, Canada and BENGALURU, Karnataka, India, June 27, 2025 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), is pleased to announce …
Kymera Therapeutics Announces Pricing of $250 Million Public Offering
GlobeNewswire
·
June 27, 2025
WATERTOWN, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the pricing …
Achieve Life Sciences Announces Pricing of $45.0 Million Underwritten Public Offering
GlobeNewswire
·
June 27, 2025
SEATTLE and VANCOUVER, British Columbia, June 26, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of …